@FierceMedDev: ICYMI yesterday: Google Life Sciences teams with AHA to target heart disease in $50M research initiative. Article | Follow @FierceMedDev
@VarunSaxena2: JAMA study: Rate of inappropriate stenting is declining. Story | Follow @VarunSaxena2
@EmilyWFierce: Scientists make strides toward full-body PET scanner with $15.5M in tow. Article | Follow @EmilyWFierce
> GE Healthcare ($GE) has acquired U.S. healthcare consultancy The Camden Group for an undisclosed sum. It will become the U.S. arm of its global advisory firm GE Healthcare Partners. More
> The Wall Street Journal is featuring a couple of med tech stories--one on medical apps and the other on hacking the brain with devices.
> Eisai's Morphotek has licensed Tumor Paint technology from Seattle, WA-based startup Blaze Bioscience to develop a means to visualize cancer cells during surgery via a tumor-targeting chlorotoxin derivative linked to a near-infrared diagnostic agent. More
Biotech News
@FierceBiotech: ICYMI yesterday: Agios slips on mixed solid tumor data for its Celgene-partnered cancer drug. More | Follow @FierceBiotech
@JohnCFierce: Old ACT was always reliable. Every fresh bit of data was a revolutionary breakthrough. But never got out of early stage R&D. | Follow @JohnCFierce
@DamianFierce: "I can't believe the future is sending feces around the country," said $MCBM's CEO, having never heard of Twitter. More from the NYT | Follow @DamianFierce
> AstraZeneca, GlaxoSmithKline stake rival claims on new lupus therapies. Story
> MiRagen captures a $41M round for a pair of microRNA trials. Article
> Did Sanofi drag its feet on Lemtrada to shortchange Genzyme shareholders? More
Pharma News
@FiercePharma: Luye's schizophrenia drug gets nod to move ahead with NDA approval. FiercePharmaAsia story | Follow @FiercePharma
@CarlyHFierce: $VRX "working hard" to reach out to payers, CEO says. "Historically, I have not spent a lot of time doing that." | Follow @CarlyHFierce
> Short-seller Citron spotlights Mallinckrodt as 'worse offender' than Valeant. Report
> J&J slapped with $1.8M verdict in Risperdal breast growth case. Article
Drug Delivery News
> Injectable HIV regimen being developed by J&J and ViiV Healthcare shows promise in trials. Report
> Canadian doctor opens blood-brain barrier using focused ultrasound. Item
> Ebola study will monitor viral entry into cells, with focus on drug delivery. Story
> Injectable HIV regimen being developed by J&J and ViiV Healthcare shows promise in trials. Article
> GSK beats AstraZeneca to finish line, wins FDA approval of first anti-IL-5 injectable for asthma. More
Pharma Manufacturing News
> Court orders Dr. Reddy's to temporarily halt sales of its purple Nexium copy. Story
> Pfizer recalls 21,000 bottles of Xanax that may be too weak. More
> Almac expanding in U.K., investing $24M in Charnwood tech park. Report
> Dr. Reddy's gets slapped with FDA warning letter for three Indian plants. Article
> Sun's U.S. sales crater as plant issues cut deeply. Story
Pharma Asia News
> AstraZeneca shows more solid gains in China on respiratory. More
> Luye's schizophrenia drug gets nod to move ahead with NDA approval. Story
> China to restart mainland IPOs, with pharma ready to roll. Item
> FDA widens review of Dr. Reddy's manufacturing ops. More
> India's Sun Pharmaceutical takes another Ranbaxy-related hit. Article